Overseas tax savings for U.S. drugmakers under threat
Eli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits overseas. The strategy has drawn the ire of some legislators.
Eli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits overseas. The strategy has drawn the ire of some legislators.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases, Bloomberg News reported. Lilly wants a court to reaffirm the patents behind its own cancer drug Erbitux. According to Lilly’s lawsuit, filed Thursday in federal court in San Francisco, Genentech deceived the U.S. Patent Office into issuing patents known as “Cabilly” after one of the inventors. Genentech claims that the process and certain starting materials used to produce Erbitux infringe on parts of the patents, and is pursuing an “aggressive litigation policy to protect its products against competition,” according to the complaint. Erbitux, made by Indianapolis-based Lilly’s ImClone unit, is approved in the United States to treat colon cancer and head and neck tumors. Lilly realized about $400 million in revenue from the drug in 2012. A phone call to Genentech’s media office seeking comment about the lawsuit wasn’t immediately returned.
Indianapolis-based CHV Capital joined Kaiser Permanente Ventures to invest an $8 million funding round for Health Catalyst, a Salt Lake City-based data warehousing company. The company already had raised $33 million in Series B funding to develop its technology, which helps hospitals measure quality data from their electronic medical record systems and report it to regulatory agencies and health insurers. Indiana University Health, the hospital system that is the parent of CHV Capital, already is using Health Catalyst’s technology.
The Indiana Senate voted last week to expand Medicaid using the state-run Healthy Indiana Plan. According to the Associated Press, Gov. Mike Pence and the Republican-led General Assembly have beat back efforts by Democrats to expand coverage using the traditional federal-state Medicaid program for the poor. Instead, they say, expansion should be done through the Healthy Indiana Plan or a similar state-run program, giving the state more control over costs. Expanding HIP would cost the state roughly 3 percent less than expanding Medicaid, state actuary Milliman Inc. estimated on Feb. 25. And supporters say HIP would promote more responsible decisions by enrollees. On the table is an expected $10.5 billion in federal aid for the state over the next seven years. But expanding HIP also could cost the state close to $2 billion over the period. House Speaker Brian Bosma, R-Indianapolis, said Tuesday that Pence likes the Senate's request for block grants from the federal government instead of matching funds for Indiana’s spending, as is the case with traditional Medicaid. "At least the leadership is all in favor of not using Medicaid expansion as the vehicle here because of the potential for massive cost in the future," Bosma said. Seven Democratic senators voted with all of the chamber's Republicans for the expansion, despite reservations about using HIP. "We don't agree with the bill the way it was written, but we want to make sure it remains alive," said Sen. Karen Tallian, D-Portage. Tallian asked lawmakers to approve a temporary expansion of Medicaid, for two years, similar to what Florida Gov. Rick Scott, a Republican, is supporting. But her amendment and similar efforts in the House failed.
Warsaw-based Zimmer Holdings Inc. said the U.S. Securities and Exchange Commission and the U.S. Department of Justice have ended their investigation into a possible violation by Zimmer of the Foreign Corrupt Practices Act. The investigation dates to September 2007. Zimmer is the world’s largest maker of orthopedic implants.
The National Science Foundation has awarded $500,000 to West Lafayette-based Tymora Analytical Operations LLC via a Phase II Small Business Innovation Research grant. Tymora will use the two-year grant to develop a technology called pIMAGO that helps lab researchers identify new targets for drugs to fight such diseases as cancer, diabetes, neurological disorders and immune system disorders. Tymora, founded by two Purdue University professors, has also received $450,000 in previous grants from the National Institutes of Health.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
Purdue University has hired a former official in Mitch Daniels' gubernatorial administration to lead the Purdue Research Foundation.
Do the politicians care what nonvoters think? House Speaker Brian Bosma recently took issue with the WISH-TV/Ball State Hoosier Survey because, he said, it wasn’t a voter poll. When challenged, he said that he cares what everybody thinks, but the message he delivered was that the opinions of voters matter more than those of adults […]
Do the politicians care what nonvoters think? House Speaker Brian Bosma recently took issue with the WISH-TV/Ball State Hoosier Survey because, he said, it wasn’t a voter poll. When challenged, he said that he cares what everybody thinks, but the message he delivered was that the opinions of voters matter more than those of adults who don’t get to the polls.
Researchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
Insiders at Indianapolis-area companies cashed in millions of dollars of their own companies’ shares this month, a selling spree that might reflect growing sentiment the market rally is ending.
A new group of 40-something professionals in central Indiana is hoping to do for education reform what the amateur sports initiative did 35 years ago: spawn a generation of leaders to work on a long-term challenge.
Roche AG and Eli Lilly and Co., two drugmakers racing to develop treatments for some of the least understood brain disorders, may gain the most from a U.S. government boost in funding to fully map the human brain.
Former Amerigroup Corp. CEO Jim Carlson will leave WellPoint Inc., the company told Bloomberg News—three days after he lost a bid for the top job at the Indianapolis-based health insurer. Carlson will leave WellPoint on Feb. 28, according to a statement e-mailed by company spokeswoman Kristin Binns. He had joined the nation's second-largest health insurer in December, after WellPoint closed its $4.9 billion acquisition of Amerigroup. WellPoint named Joe Swedish, CEO of the not-for-profit hospital system Trinity Health Corp., to be its next leader, ending a six-month search. Carlson, 60, was among the other candidates under consideration. “After helping close the Amerigroup transaction and assisting over the past six weeks with the integration of the two companies, Jim Carlson will be leaving WellPoint effective Feb. 28,” WellPoint said in the statement. While Carlson had signed a contract to remain with WellPoint for two years, the pact allowed the two sides to part under “changed circumstances,” said Carl McDonald, a Citigroup analyst, in a Feb. 13 note to clients. The WellPoint statement didn’t mention Carlson’s contract. Binns declined to comment when asked how Carlson’s contract would be handled. WellPoint said last month that Richard Zoretic, Amerigroup’s former chief operating officer, would run its Medicaid business.
In a combative Feb. 13 letter to the Obama administration, Indiana Gov. Mike Pence asked the federal government to approve a three-year extension of the Healthy Indiana Plan health savings accounts in lieu of an expansion of a federal Medicaid system. "Medicaid is broken. It has a well-documented history of substantial waste, fraud and abuse. It has failed to keep pace with private market innovations that have created efficiencies, controlled costs and improved quality," he wrote to U.S. Health and Human Services Secretary Kathleen Sebelius. According to the Associated Press, the Indiana Family and Social Services Administration requested a waiver from the Centers for Medicare and Medicaid Services, seeking to enroll residents who earn up to 138 percent of the federal poverty line in the HIP program — a move that would effectively cover roughly 400,000 residents through health savings accounts instead of traditional Medicaid. The 2010 Patient Protection and Affordable Care Act had called for all states to expand eligibility to the traditional Medicaid program for all residents making up to 138 percent of the federal poverty limit. House Minority Leader Scott Pelath, D-Michigan City, said Pence's move puts thousands of jobs at risks by playing politics with the expansion. It's unclear whether the federal agency in charge of Medicaid will sign off on a longer extension and expansion of the Indiana program. The agency approved a one-year extension last month but ruled out minimum payments. Former Gov. Mitch Daniels sought a three-year extension of the program in 2011, but was rejected.
Bioanalytical Systems Inc. swung to a profit in the quarter ended Dec. 31, the West Lafayatte-based company announced Feb. 14. The company, which conducts preclinical testing for pharmaceutical companies, earned $139,000 during the quarter, or 2 cents per share, compared with a loss in the same quarter a year ago of $1.5 million, or 21 cents per share. But revenue in the quarter fell 23 percent, compared with a year ago, to $5.8 million. Jacqueline Lemke, who was recently named CEO after serving in the role on an interim basis, said in a prepared statement: "With the notable exception of revenue, all of our operating metrics moved decisively in the right direction in the first quarter compared to the prior year. We believe these improvements are sustainable.”
A federal audit recommended that the Indiana Medicaid program refund more than $5.8 million because it failed to ensure that Logansport State Hospital had complied with special conditions for psychiatric hospitals. The audit, released Friday by the Office of Inspector General of the U.S. Department of Health and Human Services, said the hospital failed to demonstrate it met staffing and medical-record requirements from the start of 2008 through the end of 2010. So the inspector general thinks the state of Indiana should refund all federal funds used to pay that hospital during that time period—about $5.84 million—as well as any federal funds paid after 2010 if the hospital continued to be out of compliance. It's unclear whether Indiana will need to refund all the recommended amounts or when that would happen. Audits usually begin a period of negotiations between the two sides. The agency that administers the Indiana Medicaid program, the Family and Social Services Administration, issued a brief statement Friday saying the agency disagrees with the audit findings and plans to work with the federal government to reach "a reasonable resolution."
Dutch diagnostics maker Qiagen NV will work with Eli Lilly and Co. to develop companion tests that could identify patients who could be helped by Lilly's drugs. According to the Associated Press, the companies did not disclose terms of the new collaboration, but described it as a "broad" partnership that will cover "all therapeutic areas." In September 2011, Qiagen started working with Indianapolis-based Lilly on a test designed to identify patients who might be helped by an experimental blood cancer drug. In July 2012, the U.S. Food and Drug Administration approved a genetic test Qiagen developed that is designed to help doctors more quickly determine which late-stage colon cancer patients will respond to the drug Erbitux and which won't benefit from the treatment. Erbitux is marketed by Lilly and Bristol-Myers Squibb Co. In January, Lilly partnered with a unit of Agilent Technologies Inc. to develop a test that can identify cancer patients who could benefit from an experimental cancer drug Lilly is developing.
Small not-for-profits’ strategy of recruiting big-business executives for top posts has had mixed results since coming into vogue in the 1990s. For some of the executives, the transitions is a culture shock.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Indiana University Health Physicians added 39 doctors from the division of gastroenterology and hepatology at the IU School of Medicine. The group was founded in 1958 and is consistently ranked as one of the top 20 programs nationally. IU Health Physicians now employs more than 1,000 doctors. The group, which also includes five nurse practitioners, offers care at IU Health University Hospital, Wishard Health Services and the Richard L. Roudebush VA Medical Center, and will soon expand to IU Health North and IU Health Saxony hospitals. They also see patients in satellite offices in Batesville, Carmel, Greenfield, Greensburg, Lebanon, Martinsville, McCordsville and Zionsville.
Elona Biotechnologies Inc., a drugmaker trying to launch a generic version of insulin, says it has found a solution to its default on more than $8 million in economic development loans and incentives from the city of Greenwood. Elona announced Feb. 6 that it has reached an agreement under which the company will be acquired by a group of private investors. It did not disclose the names of the investors or the amount of financing. "While terms of the transaction are confidential, Elona will receive sufficient funds to correct its default situation with the city of Greenwood, hire management and scientific talent to move the company forward, and proceed with clinical trials to support the registration of its generic human insulin under development for the treatment of diabetes," the company said in a prepared statement. An executive team of pharmaceutical industry veterans with extensive experience will join Elona as staff or consultants, the company said. The company told Greenwood officials of its financial troubles in late January. That information prompted the Greenwood Redevelopment Commission to vote to declare Elona in default on $8.4 million worth of economic development incentives the city approved for the company in 2010. The city loaned $6.4 million to help Elona build a 50,000-square-foot, $28 million insulin production plant in Greenwood and hire 70 workers. The city also gave Elona $1.5 million to help it win approval for its insulin from the U.S. Food and Drug Administration and $500,000 for equipment.
Eli Lilly and Co. said it is halting testing of an experimental drug for rheumatoid arthritis because the studies show the medicine is not effective. The decision to stop testing the therapy, called tabalumab, in rheumatoid arthritis wasn’t based on safety concerns, the Indianapolis-based drugmaker said Feb. 7 in a prepared statement. Lilly said it will continue to develop the drug as a treatment for lupus. In December, Lilly said it was stopping one of three late-stage rheumatoid arthritis studies of tabalumab after it failed to provide a benefit. Lilly then analyzed the other two studies and determined the drug was unlikely to help patients. The setback comes as Lilly, counting on sales of new medicines to revive growth, faces generic competition to schizophrenia drug Zyprexa, which generated $5 billion in annual revenue before losing patent protection in October 2011.
With all the talk about increasing health care costs, the Affordable Care Act and Hoosiers’ poor health standings, now is the time for Indianapolis to be bold and take action.
Don Marsh’s testimony on cross-examination Thursday morning revealed a defense strategy to convince jurors that the frequent trips the former CEO took on the company’s dime were more for business than pleasure.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
Elona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development incentives, says it has solution to its financial problems.
House Republican leaders toured an Indianapolis preschool Wednesday, one day before the House Education Committee takes up a proposal to give preschool vouchers to low-income families in a small number of cases.
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.